INTRODUCTION {#SEC1}
============

Cyclodipeptide synthases (CDPSs) form a family of tRNA-dependent enzymes that catalyse the synthesis of various cyclodipeptides, which are the precursors of various secondary metabolites with important biological activities ([@B1]). CDPSs use two aminoacyl-tRNA (aa-tRNA) substrates in a sequential ping-pong mechanism to form the two peptide bonds of cyclodipeptides ([@B4]). The first catalytic steps involve the binding of the first aa-tRNA to the CDPSs and the subsequent transfer of the aminoacyl moiety onto an active-site serine residue to form an acyl-enzyme intermediate. The acyl-enzyme then reacts with the aminoacyl moiety of the second aa-tRNA substrate to form a dipeptidyl intermediate that undergoes intramolecular cyclisation, yielding the final cyclodipeptide product.

Crystal structures are available for three CDPSs ([@B4]). The three CDPSs share an architecture that is very similar to the catalytic domain of class-I aminoacyl-tRNA synthetases (aaRSs), especially class-Ic TyrRSs and TrpRSs. Conventional aaRSs catalyse the formation of aa-tRNAs in a two-step reaction consisting of activation of the amino acid by formation of an aminoacyl-adenylate intermediate, followed by esterification at the 3'-hydroxyl of a cognate tRNA. CDPSs would have diverged from conventional aaRSs and acquired new active site residues, converting them into cyclodipeptide-forming enzymes, for which aa-tRNAs are the substrates instead of the final products ([@B8]). This evolutionary event would have entailed significant divergence between CDPSs and class-Ic aaRSs ([@B4]). First, class-Ic aaRSs are homodimers that have interdigitation of the two active sites at the dimer interface whereas CDPSs are active as monomers. Second, the specific signature motifs involved in ATP binding are absent in CDPSs, consistent with the absence of ATP-dependent activation by CDPSs. Third, the tRNA-binding domain involved in interaction with the anti-codon loop of tRNA in aaRSs is absent in CDPSs. CDPSs possess instead a large patch of positively charged residues that are absent in aaRSs. Finally, unlike aaRSs, CDPSs exhibit a large tRNA substrate specificity. Although each characterized CDPS preferentially synthesizes one predominant cyclodipeptide, most of these enzymes are promiscuous and produce several cyclodipeptides. For example, AlbC from *Streptomyces noursei* synthesizes cyclo([l]{.smallcaps}-Phe-[l]{.smallcaps}-Leu) (cFL) and Ndas_1148 from *Nocardiopsis dassonvillei* synthesizes cyclo([l]{.smallcaps}-Phe-[l]{.smallcaps}-Tyr) (cFY), but both enzymes produce appreciable amounts of other phenylalanyl-containing cyclodipeptides (cyclo([l]{.smallcaps}-Phe-[l]{.smallcaps}-X), in which X indicated any of the incorporated amino acids) (cFX). Rv2275 from *Mycobacterium tuberculosis* mostly produces cYY but also cYX cyclodipeptides, and the YvmC enzymes from *Bacillus* species mainly produce cLL and cLX compounds ([@B2],[@B9]).

No crystal structure has yet been obtained for a CDPS in complex with a ligand representative of its natural substrates. Nevertheless, the structural similarity between CDPSs and aaRSs, and extensive mutagenesis analyses of CDPSs have provided insight into the interaction of these enzymes with their aa-tRNA substrates ([@B4]). CDPSs have a surface-accessible pocket containing the catalytic residues that superimposes well with the amino acid-binding pocket of class-Ic aaRSs. This pocket accommodates the aminoacyl moiety of one of the two aa-tRNA substrates ([@B5]). The cyclodipeptides formed by a given CDPS almost invariably have one amino acid in common. This suggests that only the aminoacyl group of the first substrate, probably the 'common' aminoacyl group, binds and remains in the catalytic pocket, whereas the second substrate is probably accommodated at a different site with less stringent recognition ([@B6]). The involvement of the tRNA moiety of either substrate in substrate binding and selectivity is poorly documented. Mutagenesis studies and tRNA-binding assays identified two regions of CDPSs that are likely to interact with tRNA: the positively charged patch mentioned above and a loop located between helices α6 and α7 ([@B5],[@B6]).

Here, we studied the interaction of CDPSs with their two aa-tRNA substrates. To discriminate the interaction of either substrate with the enzyme, we worked with AlbC that uses two different substrates, Phe-tRNA^Phe^ and Leu-tRNA^Leu^, to catalyse cFL synthesis. We show that Phe-tRNA^Phe^ is specifically bound in the first step of the reaction. We also show the involvement of the nucleotide sequence of the acceptor stem in the recognition of the tRNA moiety of the second substrate and identify key bases involved in substrate specificity. Finally, we explored the role of residues predicted to interact with the tRNA moiety of the substrates and demonstrated that AlbC possesses different binding sites for its two aa-tRNA substrates.

MATERIALS AND METHODS {#SEC2}
=====================

Mutagenesis and purification of AlbC variants {#SEC2-1}
---------------------------------------------

Genes coding the six new single point variants of AlbC (R80A, R102A, N159A, R160A, D163A, D205A) were obtained via polymerase chain reaction (PCR) mutagenesis of the plasmid pQE60-AlbC encoding C-terminal His~6~-tagged AlbC ([@B5]) according to the QuikChange^TM^ site-directed mutagenesis method (Stratagene). Sequences were verified by DNA sequencing. Plasmids encoding the other AlbC variants used in this study (R91A, K94A, R98A, R98A-R99A) were constructed previously ([@B5]).

The C-terminal His~6~-tagged proteins were produced and purified as described previously ([@B2],[@B5]). Purified proteins were quantified by UV spectrophotometry. Protein molecular weights were verified by electrospray ionisation mass spectrometry (Esquire HCT ion trap mass spectrometer (Bruker Daltonik, GmbH)).

*In vitro* transcription/semi-synthesis {#SEC2-2}
---------------------------------------

tRNA^Phe^, tRNA^Leu^ isoacceptors and tRNA^LeuTAA^ mutants were obtained by *in vitro* transcription of double-stranded DNA templates ([@B10]). Double-stranded DNA templates were synthesized by PCR using three synthetic DNA oligonucleotides purchased from Eurogentec. For site-directed mutagenesis of the acceptor stem, the first oligonucleotide (Matrix) includes complementary sequence of the tRNA from positions 8 to 65. To avoid mis-transcription products, a second oligonucleotide (Forward) containing the T7 promoter sequence is fused to the tRNA sequence from positions 1 to 26. Finally, a third oligonucleotide (Reverse) includes the complementary sequence of the tRNA from positions 47 to 76. Sequences of the oligonucleotides used for synthesis of tRNA^Phe^ and tRNA^Leu^ isoacceptors are given in Supplementary Table S1. Amplified double-stranded DNA templates are used for *in vitro* transcription with T7 RNA polymerase as previously described ([@B11]) except for A^1^-U^72^ tRNA^LeuTAA^ where guanosine monophosphate (GMP) is replaced by adenosine monophosphate (AMP). Transcripts of tRNA were separated from the reaction mixture by extraction with phenol/chloroform and precipitation with ethanol. The tRNAs were purified by size exclusion chromatography (Superdex^®^ 75 HR 10/30, GE Healthcare). The concentrations of tRNAs were determined by absorption at 260 nm (1 OD~260~ unit equivalent to 40 μg/ml) and were further corrected by plateau charging (see below).

Cloning, mutagenesis and purification of *Escherichia coli* tRNA {#SEC2-3}
----------------------------------------------------------------

The plasmid encoding tRNA^Phe^, pBSTNAV2/tRNA^Phe^, was a gift from Y. Mechulam (Ecole Polytechnique, Palaiseau, France) ([@B12]). The plasmid encoding tRNA^LeuCAG^ was constructed as follows: tRNA^LeuCAG^ was amplified from a lysate of *E. coli* K12 using Thermo Scientific Phusion High-Fidelity DNA polymerase according to the manufacturer\'s guidelines. The primers used included *Eco*RI and *Pst*I restriction sites (underlined) as follows: CTTGTAACGCT[GAATTC]{.ul}GCGAAGGTGGCGGAATTG (forward) and CGCTAAGGAT[CTGCAG]{.ul}TGGTGCGAGGGGGGGG (reverse). Amplified fragments were digested by FastDigest *Eco*RI and *Pst*I (Thermo Scientific) and ligated into the digested pBSTNAV2 vector using T4 DNA ligase (Thermo Scientific) according to the manufacturer\'s protocol.

The two double mutants C^1^-G^72^ tRNA^LeuCAG^ and C^1^-G^72^ tRNA^Phe^ were obtained from wild-type sequences cloned into a pBSTNAV2 vector by amplification with oligonucleotides containing the desired mutation (in bold): LeuG1C (GTAACGCT[GAATTC]{.ul}**C**CGAAGGTGGCGGAATTG), LeuC72G (CTAAGGAT[CTGCAG]{.ul}TGGT**C**CGAGGGGGG), PheG1C (CTTGTAACGCT[GAATTC]{.ul}**C**CCCGGATAGCTCAGTC), PheC72G (CGCTAAGGAT[CTGCAG]{.ul}TGGT**C**CCCGGACTCGGAATC). Amplified fragments were treated as described above for wild-type sequences. All constructions were verified by DNA sequencing.

Production and purification of tRNAs were performed as previously described ([@B13]). Briefly, cells overexpressing tRNAs were harvested by centrifugation and tRNAs were extracted by phenol followed by centrifugation steps and precipitation with ethanol. The pellet was suspended in 20 mM Tris-HCl pH 7.5, 0.1 mM EDTA, 8 mM MgCl~2~, 0.2 M NaCl and tRNAs were purified by Q-Sepharose Fast Flow column with a linear gradient of 0.4 M to 0.7 M NaCl. The fractions containing tRNAs were precipitated by isopropanol and stored at −20°C after centrifugation and suspension in water.

Acylation of tRNAs {#SEC2-4}
------------------

The concentration of aminoacylated tRNA was determined from plateau charging experiments. The assay was performed in buffer A (50 mM HEPES-KOH pH 7.5, 150 mM KCl, 15 mM MgCl~2~, 0.1 mM EDTA, 2 mM ATP, 10 mM ß-mercaptoethanol) with 1 μM PheRS or LeuRS and 50 μM of radiolabelled amino acids ([l]{.smallcaps}-\[^14^C\]Leu, 324 mCi/mmol (12.0 GBq mmol^−1^), or [l]{.smallcaps}-\[^14^C\]Phe, 487 mCi/mmol (18.0 GBq mmol^−1^), Perkin-Elmer). The reaction was incubated for 10 min at 30°C and aa-tRNAs were precipitated with 5% TCA and 0.5% casamino acids, filtered on Whatman GF/C filters and quantified by liquid scintillation counting. Mutated tRNAs were aminoacylated for different times; 15 min was enough to ensure complete acylation.

AlbC coupled assay {#SEC2-5}
------------------

The CDPS activity of AlbC was determined in a coupled assay containing aaRSs to generate *in situ* the aa-tRNA substrates as described previously ([@B7]). The standard assay was performed in buffer A, with 50 μM Phe and Leu, 50 nM AlbC or AlbC variant, 1 μM PheRS and LeuRS, and aa-tRNAs at the concentrations specified in the text. The reaction was carried out at 30°C with a preincubation of 15 min with the aaRSs prior to the addition of AlbC for the synthesis of aa-tRNAs. Under these conditions, the tRNAs were completely acylated at the beginning of the AlbC reaction and remained acylated during the entire reaction (Supplementary Figure S1). The enzymatic reaction was initiated by the addition of AlbC. Aliquots were withdrawn at various times, acidified with 2% TFA to stop the reaction and mixed with known concentrations of stable isotope internal standards (^13^C~9~,^15^N-labelled cFF and cFL solutions), prior to cFF and cFL quantification by liquid chromatography coupled to mass spectrometry (LC-MS) as described previously ([@B2],[@B7]).

Detection of acyl-enzyme intermediates {#SEC2-6}
--------------------------------------

Purified AlbC wild-type, pSHaeC06 (positive controls), AlbC S37A (negative control) and AlbC variants were incubated with \[^14^C\]Phe-tRNA^Phe^ or \[^14^C\]Leu-tRNA^LeuCAG^ (0.5 μM). The labelled substrates were obtained as described previously ([@B5]). The enzyme was added at a final concentration of 1 μM. After 30 s of incubation, the reaction was quenched and analysed. Radioactivity was detected on polyvinylidene difluoride (PVDF) membranes by a Beta-Imager^TM^ 2000 (Biospace) ([@B5]).

RESULTS {#SEC3}
=======

AlbC discriminates Phe-tRNA^Phe^ and Leu-tRNA^Leu^ {#SEC3-1}
--------------------------------------------------

### Post-transcriptional modification of tRNAs is not required for AlbC activity {#SEC3-1-1}

We previously showed that AlbC is active when it is produced in *E. coli*. AlbC mainly synthesizes cFL but also produces appreciable amounts of other L-Phe-containing cyclodipeptides, especially cFF ([@B2]). We also showed that AlbC is active *in vitro*. The purified enzyme can use aminoacylated tRNA^Phe^ purified from *E. coli* as the substrates to produce cFF ([@B2],[@B5],[@B7]). Based on these findings, we performed all experiments described herein using the sequences of *E. coli* tRNAs, in particular that of the unique tRNA^Phe^ isoacceptor. To determine the importance of post-transcriptional modifications of tRNA^Phe^ on AlbC activity, we compared its cFF-synthesizing activity using tRNA^Phe^ either purified from *E. coli* or obtained by *in vitro* transcription. We used a coupled PheRS-AlbC assay to generate Phe-tRNA^Phe^ *in situ* and measure the time course for the synthesis of cFF at various concentrations of Phe-tRNA^Phe^ (Supplementary Figure S2) ([@B7]). The rates of formation of cFF were deduced from individual kinetics and plotted against Phe-tRNA^Phe^ concentrations (Figure [1A](#F1){ref-type="fig"}). The rate of formation of cFF was similar, regardless of the Phe-tRNA^Phe^ used. This result shows that post-transcriptional modification of the tRNA^Phe^ is not essential for enzymatic activity. The tRNAs used in subsequent experiments were obtained by *in vitro* transcription, except where otherwise stated.

![(**A**) cFF-synthesizing activity of AlbC using either tRNA^Phe^ purified from *E. coli* (blue) or tRNA^Phe^ obtained by *in vitro* transcription (orange). Enzymatic measurements were performed as described in 'Materials and Methods' with 50 nM AlbC. The points reported are the result of three independent experiments. Error bars show the uncertainty on measurement. (**B**) Rate of formation of cFL (left panel) or cFF (right panel) by AlbC for different tRNA^Leu^ isoacceptors. Kinetics of synthesis were determined with 0.2 μM Phe-tRNA^Phe^ and three concentrations of Leu-tRNA^Leu^. Isoacceptors are identified by the following colours: tRNA^LeuCAA^ (light blue), tRNA^LeuTAG^ (dark blue), tRNA^LeuGAG^ (yellow), tRNA^LeuTAA^ (orange), tRNA^LeuCAG\*^ (grey), tRNA^LeuCAG^ (black). Curves are drawn for clarity and are not representative of kinetic models. (**C**) Covalent labelling of AlbC, S37A and pSHaeC06 (pSH) by \[^14^C\]Phe transferred from \[^14^C\]Phe-tRNA^Phe^ or \[^14^C\]Leu transferred from \[^14^C\]Leu-tRNA^LeuCAG^. Enzymes were incubated with labelled aa-tRNA, as described in 'Materials and Methods', separated on SDS-PAGE, then transferred onto a PVDF membrane that was analysed with a radioimager.](gku348fig1){#F1}

### AlbC does not use all Leu-tRNA^Leu^ isoacceptors {#SEC3-1-2}

We tested the cyclodipeptide-synthesizing activity of AlbC using both Phe-tRNA^Phe^ and Leu-tRNA^Leu^ as substrates. While the tRNA^Phe^ sequence is unique, *E. coli* possesses six different tRNA^Leu^ isoacceptors, two of which differ from each other only by one base in the variable loop (tRNA^LeuCAG^/tRNA^LeuCAG\*^) (Supplementary Figure S3). We determined the kinetics of cFL, cFF and cLL synthesis by the coupled aaRS-AlbC assay for a fixed concentration of Phe-tRNA^Phe^ (0.2 μM) and various concentrations of each of the six tRNA^Leu^ isoacceptors. Formation of cLL was not detected in our experimental conditions, regardless of the sequence and concentration of tRNA^Leu^ isoacceptor. The rates of formation of the cyclodipeptides cFL and cFF were deduced from individual kinetics and plotted against Leu-tRNA^Leu^ concentrations for each isoacceptor (Figure [1B](#F1){ref-type="fig"}). Leu-tRNA^Leu^ isoacceptors were not used with the same catalytic efficiency by AlbC. The rates of cFL formation (Figure [1B](#F1){ref-type="fig"}, left panel) were the highest for Leu-tRNA^LeuCAG^ or Leu-tRNA^LeuCAG\*^, two times lower for Leu-tRNA^LeuCAA^ or Leu-tRNA^LeuTAG^, and close to zero for Leu-tRNA^LeuGAG^ or Leu-tRNA^LeuTAA^. AlbC synthesized higher quantities of cFF than cFL for equivalent concentrations of Phe-tRNA^Phe^ and Leu-tRNA^Leu^ (i.e. 0.2 μM), regardless of the Leu-tRNA^Leu^ isoacceptor used (Figure [1B](#F1){ref-type="fig"}). Thus, AlbC used more efficiently Phe-tRNA^Phe^ than any of the Leu-tRNA^Leu^. The efficiency of cFF synthesis was not affected by the presence of Leu-tRNA^LeuGAG^ or Leu-tRNA^LeuTAA^ indicating that these molecules do not compete with Phe-tRNA^Phe^ for binding to AlbC (Figure [1B](#F1){ref-type="fig"}, right panel). In contrast, the other four Leu-tRNA^Leu^ isoacceptors inhibited cFF synthesis revealing a competition with Phe-tRNA^Phe^.

### Phe-tRNA^Phe^ is the first substrate accommodated by AlbC {#SEC3-1-3}

The CDPSs AlbC, Rv2275, YvmC-Blic and *Nvec*-CDPS2 have a common first catalytic step. This step involves the binding of the first aa-tRNA substrate to the enzyme and the subsequent transfer of its aminoacyl moiety onto the conserved serine residue of the catalytic pocket to form an acyl-enzyme intermediate ([@B4]). In all four cases, the formation of the acyl-enzyme was tested using a unique aa-tRNA as a substrate since these enzymes synthesize homocyclodipeptides (cYY for Rv2275 and cLL for YvmC-Blic; cFF for AlbC and *Nvec*-CDPS2). We used the property of AlbC to synthesize the heterocyclodipeptide cFL to investigate substrate-binding order. AlbC was incubated with either \[^14^C\]Phe-tRNA^Phe^ or \[^14^C\]Leu-tRNA^LeuCAG^ and the formation of an acyl-enzyme intermediate was determined by autoradiography following sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transfer onto a PVDF membrane ([@B5]). Formation of \[^14^C\]AlbC was detected with \[^14^C\]Phe-tRNA^Phe^ but not with \[^14^C\]Leu-tRNA^LeuCAG^ (Figure [1C](#F1){ref-type="fig"}), indicating that Phe-tRNA^Phe^ is the first substrate of AlbC. As a negative control, we showed that an inactive AlbC variant carrying a S37A substitution ([@B5]) was not labelled upon incubation with \[^14^C\]Phe-tRNA^Phe^ in the same conditions. As a positive control for the formation of an acyl-enzyme with \[^14^C\]Leu-tRNA^LeuCAG^, we used CDPS pSHaeC06 from *Staphylococcus haemolyticus*, which mainly synthesizes cLL ([@B2]). Finally, the LS-MS/MS coupled assay with unlabelled substrates was used to check that the AlbC and pSHaeC06 enzyme preparations used for these experiments were fully functional.

Specificity determinants in aa-tRNAs substrates of AlbC {#SEC3-2}
-------------------------------------------------------

### The pair G^1^-C^72^ of the second substrate is essential for cFL synthesis {#SEC3-2-1}

Comparison of the sequences of the six tRNA^Leu^ isoacceptors of *E. coli* revealed that a wobble base pair G^1^•U^72^ is present in the distal position of the acceptor arm of the two tRNA^Leu^ isoacceptors that are not used as substrates by AlbC, i.e. Leu-tRNA^LeuGAG^ and Leu-tRNA^LeuTAA^. In contrast, the four other Leu-tRNA^Leu^ isoacceptors and Phe-tRNA^Phe^ possess a canonical G^1^-C^72^ base pair at this position (Figures [1B](#F1){ref-type="fig"} and [2A](#F2){ref-type="fig"}). We introduced a U to C base substitution at position 72 of tRNA^LeuTAA^ to restore a G^1^-C^72^ Watson--Crick base pair in the acceptor arm of this tRNA. A second tRNA^LeuTAA^ mutant was constructed by introducing an A^1^-U^72^ base pair at the same position. tRNA^LeuTAA^ was preferred to tRNA^LeuGAG^ for this analysis since the acceptor stems tRNA^LeuTAA^ and tRNA^Phe^ only differ by U and C at position 72 (Figure [2A](#F2){ref-type="fig"}). This allowed comparison of Phe-tRNA^Phe^ with a Leu-tRNA^LeuTAA^ variant containing identical acceptor stems. The mutants were used as substrates in the coupled aaRS-AlbC assay. This assay was carried out as described above for the screening of Leu-tRNA^Leu^ isoacceptors, except that the KCl concentration was 50 mM instead of 150 mM, to maximize enzymatic activity. Leu-tRNA^LeuTAA^ and Leu-tRNA^LeuCAG^ were analysed in the same experimental conditions for comparison. The results are presented in Figure [2B](#F2){ref-type="fig"}. The U^72^C mutation in Leu-tRNA^LeuTAA^ resulted in an enzymatic activity close to that measured for the best isoacceptor, Leu-tRNA^LeuCAG^. The G^1^A mutation in Leu-tRNA^LeuTAA^ did not enable the significant formation of cFL, as observed for its wild-type counterpart, Leu-tRNA^LeuTAA^. Our results clearly show that the pair G^1^-C^72^ is a key identity determinant for the second substrate of AlbC.

![(**A**) Sequences of the acceptor arm of the natural and mutant tRNAs used in this study. (**B**) Rate of formation of cFL (left panel) and cFF (right panel) by AlbC using tRNA^LeuTAA^ mutants: G^1^-C^72^ tRNA^LeuTAA^ (grey) or A^1^-U^72^ tRNA^LeuTAA^ (light blue). Wild-type tRNA^LeuTAA^ (orange) was used as a control and tRNA^LeuCAG^ (black) as a reference of substrate recognized by AlbC. Kinetics of synthesis were determined as for experiments shown in Figure [1](#F1){ref-type="fig"}, except for KCl concentration (see results). Curves are drawn for clarity and are not representative of kinetic models.](gku348fig2){#F2}

In addition, we investigated the capacity of G^1^-C^72^ tRNA^LeuTAA^, which has an acceptor stem identical to that of tRNA^Phe^, to bind AlbC as a first substrate. We did not detect any signal using \[^14^C\]Leu G^1^-C^72^ tRNA^LeuTAA^ as a substrate in the acyl-enzyme formation assay (Supplementary Figure S4). Formation of cLL was also not detected using G^1^-C^72^ tRNA^LeuTAA^ as the sole substrate. Thus, the sequence of the tRNA^Phe^ acceptor stem is not the key identity determinant for the first substrate of the reaction.

### Recognition of the sequence G^1^-C^72^ versus C^1^-G^72^ for the two substrates of AlbC {#SEC3-2-2}

The last base pair of the acceptor stem of tRNA^Tyr^ is a key element for the recognition of this tRNA by TyrRSs. This base pair is responsible for the absence of cross reactivity between archeal or eukaryotic TyrRS-tRNA^Tyr^ and bacterial TyrRS-tRNA^Tyr^ (recognition of C^1^-G^72^ and G^1^-C^72^, respectively) ([@B14],[@B15]). To investigate whether AlbC can also discriminate G^1^-C^72^ from C^1^-G^72^, we constructed the C^1^-G^72^ tRNA^Phe^ and C^1^-G^72^ tRNA^LeuCAG^ mutants (tRNA^LeuCAG^ being the best tRNA^Leu^ isoacceptor substrate). These two mutants could not be obtained by *in vitro* transcription. They were constructed by mutagenesis from natural tRNAs and produced by overexpression in *E. coli*. The cFF-synthesizing activity of AlbC was more than 10-fold lower with the C^1^-G^72^ tRNA^Phe^ mutant than for the wild-type tRNA^Phe^ (Figure [3A](#F3){ref-type="fig"}) whereas similar amounts of phenylalanyl-enzyme were formed (Figure [3B](#F3){ref-type="fig"}). These results show that AlbC does not discriminate G^1^-C^72^ from C^1^-G^72^ for the first substrate but does for the second one. This conclusion was also supported by comparison C^1^-G^72^ and wild-type tRNA^LeuCAG^ as the second substrate. The formation of cFL was strongly decreased by the C^1^-G^72^ mutation and inhibition of cFF was also reduced (Figure [3C](#F3){ref-type="fig"}). As a wild-type tRNA^LeuCAG^ reference, we used tRNA^LeuCAG^ produced by overexpression in *E. coli*. The rates of cFL or cFF synthesis were similar to those observed with tRNA^LeuCAG^ obtained by *in vitro* transcription (Figure [3C](#F3){ref-type="fig"}), indicating that post-transcriptional modification of the second aa-tRNA substrate is not essential for enzymatic activity.

![(**A**) cFF-synthesizing activity of AlbC using either Phe-tRNA^Phe^ purified from *E. coli* (black/grey) or Phe C^1^-G^72^ tRNA^Phe^ (orange/yellow). The points reported are the result of two independent experiments. Error bars show the uncertainty on measurement. Curves are drawn for clarity and are not representative of kinetic models. Enzymatic measurements were performed as described in 'Materials and Methods' with 50 nM AlbC. (**B**) Covalent labelling of AlbC and S37A by \[^14^C\]Phe-tRNA^Phe^ or \[^14^C\]Phe C^1^-G^72^ tRNA^Phe^. Enzymes were incubated with labelled aa-tRNA, as described in 'Materials and Methods', separated on SDS--PAGE, then transferred onto a PVDF membrane that was analysed with a radioimager. (**C**) Rate of formation of cFL (left panel) and cFF (right panel) by AlbC using tRNA^LeuCAG^ obtained by *in vitro* transcription (black), tRNA^LeuCAG^ purified from *E. coli* (grey) or Leu C^1^-G^72^ tRNA^LeuCAG^ (orange). Kinetics of synthesis were determined as described in Figure [1](#F1){ref-type="fig"}. Curves are drawn for clarity and are not representative of kinetic models.](gku348fig3){#F3}

Regions of AlbC involved in interaction with tRNAs {#SEC3-3}
--------------------------------------------------

### Interaction of aa-tRNAs with the basic patch of AlbC {#SEC3-3-1}

We previously substituted each of the basic residues located in helix α4 with alanine. When expressed in *E. coli*, most of the resulting variants produced lower amounts of cFL than the wild-type enzyme, suggesting that these basic residues interact with the tRNA moiety of the substrates ([@B5]). We selected and purified AlbC variants encompassing residues distributed across the whole basic patch, namely R80A, R91A, K94A, R98A, R102A and R98A/R99A (Figure [5](#F5){ref-type="fig"}). We first investigated the propensity of the variants to form the acyl-enzyme intermediate with either Phe-tRNA^Phe^ or Leu-tRNA^LeuCAG^. Similar to the wild-type enzyme, labelled intermediates were only detected in the presence of \[^14^C\]Phe-tRNA^Phe^, indicating that Phe-tRNA^Phe^ was also the first substrate accommodated by each of the variants (Figure [4A](#F4){ref-type="fig"} and Supplementary Figure S5). The amount of phenylalanyl-enzyme detected was decreased for all variants. In particular, substitutions of residues R98 and R99 located in the C-terminal part of helix α4 prevented acylation. These results show that the basic patch of helix α4 of AlbC is involved in the binding of the first substrate Phe-tRNA^Phe^.

![Covalent labelling of AlbC and variants by \[^14^C\]Phe transferred from \[^14^C\]Phe-tRNA Phe. AlbC was used as positive control for the formation of phenylalanyl-enzyme and S37A was used as a negative control in this experiment (not shown). Enzymes were incubated with labelled aa-tRNA, as described in 'Materials and Methods', separated on SDS--PAGE, then transferred onto a PVDF membrane that was analysed with a radioimager. Detection of potential leucyl-enzyme intermediates is shown in Supplementary Figure S5. (**A**) Variants of the basic patch. (**B**) Variants of the loops α6--α7 and β6--α8. Proteins were analysed on different gels. AlbC was loaded onto each gel as a standard.](gku348fig4){#F4}

![AlbC regions involved in interaction with tRNA substrates. The overall structure of AlbC (PDB, 3OQV) is shown in surface mode. The patch of basic residues located on helix α4 is coloured in blue; the residues substituted in this study are in dark blue. The loop α6--α7 is coloured in green; the residues substituted in this study are in dark green. The residue D205 belonging to the loop β6- α8 is coloured in dark red.](gku348fig5){#F5}

We wondered if information regarding the binding of the second substrate could be obtained from measuring the activity of these different variants. We used Phe-tRNA^Phe^ and three different Leu-tRNA^Leu^ isoacceptors representative of the different activity patterns observed for wild-type AlbC (Leu-tRNA^LeuCAG^, Leu-tRNA^LeuCAA^ and Leu-tRNA^LeuTAA^, see Figure [1B](#F1){ref-type="fig"}). In standard assay conditions (50 nM AlbC or AlbC variant, 0.25 μM Phe-tRNA^Phe^ and 0.22 μM Leu-tRNA^Leu^ isoacceptor), the amounts of cyclodipeptides produced by the variants were under the detection threshold (25--30 nM). We modified the experimental conditions so that enzyme/substrate ratios were set at values similar to those used in the acyl-enzyme detection assay (i.e. 1.5 μM AlbC or AlbC variant, 0.75 μM Phe-tRNA^Phe^ and 0.66 μM Leu-tRNA^Leu^ isoacceptor). All of the variants showed lower cyclodipeptide-synthesizing activity than the wild-type enzyme; the more affected being the variant R98A/R99A (Table [1](#T1){ref-type="table"}A). For each variant, the cFL- and cFF-synthesizing activities were decreased by the same factor, regardless of the tRNA^Leu^ isoacceptor used. As none of the substitutions changed the pattern of use of the second substrate, it is likely that the basic residues of the helix α4 are not involved in its binding.

###### cFF and cFL synthesis activity of AlbC variants with different tRNA^Leu^ isoacceptors

  ---------------------
  ![](gku348tbl1.jpg)
  ---------------------

Activities are expressed in concentration of cyclodipeptides (nM) after 21 min of reaction; D, detectable. (**A**) The standard enzymatic assay was performed with 0.75 μM Phe-tRNA^Phe^, 0.66 μM Leu-tRNA^Leu^ isoacceptor and 1.5 μM AlbC or AlbC variant (50 mM KCl). Under these conditions, wild-type AlbC catalysed the complete incorporation of Phe into cFL and cFF. An additional assay was performed in non-limiting conditions using 150 nM AlbC (1/10). (**B**) The most active variants were tested with diluted concentrations of enzyme and both tRNA substrates. The enzymatic assay was performed with 0.25 μM Phe-tRNA^Phe^, 0.22 μM Leu-tRNA^Leu^ isoacceptor and 300 nM AlbC or AlbC variant (50 mM KCl). Residual activity (% of wild-type activity) is in grey.

### Implication of other AlbC residues in tRNA interaction {#SEC3-3-2}

Bonnefond *et al.* showed that deletion of the R158-V166 region that corresponds to the loop α6--α7 abolished non-acylated tRNA^Leu^ binding to CDPS YvmC (PDB, 3OQH) ([@B6]). To evaluate the role of this region of AlbC in tRNA binding, we substituted polar residues N159, R160, D163 and D205 with alanine (D205 belongs to the loop β6--α8 but is close to N159; Figure [5](#F5){ref-type="fig"}). Incubation of the variants with \[^14^C\]Phe-tRNA^Phe^ indicated that substitutions N159A, R160A and D163A did not affect phenylalanyl-enzyme formation (Figure [4B](#F4){ref-type="fig"}). No labelled enzyme was detected with \[^14^C\]Leu-tRNA^Leu^ (Supplementary Figure S5). These results show that this region of AlbC is not involved in the binding of the first substrate. For the variant D205A, more labelled phenylalanyl-enzyme was detected (Figure [4B](#F4){ref-type="fig"}). This was the only variant for which a significant amount of leucyl-enzyme intermediate was also detected (Supplementary Figure S5).

We next determined the activity of these variants in the presence of the different Leu-tRNA^Leu^ isoacceptors (Table [1](#T1){ref-type="table"}A). The N159A and R160A substitutions decreased cyclodipeptide production. Synthesis of cFL was more affected than that of cFF. Furthermore, the decrease in activity of the variant N159A varied according to the tRNA^Leu^ isoacceptor used. These results suggest an involvement of both residues in the binding of the second substrate. For the variants D163A and D205A, as for the wild-type enzyme, the phenylalanine present in the enzymatic assay was completely incorporated into cFF and cFL, preventing a comparison of their activities. A new measurement was performed with reduced concentrations of enzyme and substrates (i.e. 300 nM enzyme, 0.25 μM Phe-tRNA^Phe^ and 0.22 nM Leu-tRNA^LeuCAG^) (Table [1](#T1){ref-type="table"}B). Both variants synthesized much more cFF and cFL than the wild-type enzyme. In addition, the pattern of use of the different isoacceptors tRNA^Leu^ changed. Both variants used preferentially tRNA^LeuCAA^, followed by tRNA^LeuCAG^, and then by tRNA^LeuTAA^. These results show that modification of residues D163 and D205 changed tRNA^Leu^ isoacceptor specificity, indicating their involvement in the binding of the second substrate.

DISCUSSION {#SEC4}
==========

Here, we show that AlbC discriminates between its two substrates and possesses a different binding site for each of them.

AlbC first specifically interacts with Phe-tRNA^Phe^, forming a phenylalanyl-enzyme intermediate. Phenylalanine is also the amino acid preferentially incorporated into cyclodipeptides synthesized by AlbC. This confirms the previous assumption that the preferred amino acid is first bound to the CDPS and remains in the catalytic pocket as an acyl-enzyme intermediate ([@B3],[@B5],[@B6]). We did not detect a covalent leucyl-enzyme intermediate when leucylated G^1^-C^72^ tRNA^LeuTAA^ was used as a substrate. The acceptor arm sequence of G^1^-C^72^ tRNA^LeuTAA^ is identical to that of tRNA^Phe^. This indicates that the nature of the amino acid loaded onto tRNA is a key determinant of the specificity of AlbC for its first substrate.

We analysed the interaction of AlbC with Leu-tRNA^Leu^ as a second substrate by measuring its enzymatic activity with each of the six different tRNA^Leu^ isoacceptors. AlbC does not use all of the Leu-tRNA^Leu^ isoacceptors as a second substrate, implying the involvement of the tRNA moiety in the recognition of the second substrate. The two tRNAs^Leu^ not used as substrates (tRNA^LeuTAA^ and tRNA^LeuTAG^) are the only ones to have a U base at position 72. Mutation of this position (U^72^C) in tRNA^LeuTAA^ was sufficient for high AlbC activity. This mutation restores a Watson--Crick base pair G^1^-C^72^. However, despite the presence of Watson--Crick base pairing, the A^1^-U^72^ tRNA^LeuTAA^ mutant is not a substrate of AlbC, and the C^1^-G^72^ tRNA^LeuCAG^ mutant is a poor substrate of AlbC. The base pair G^1^-C^72^ of the acceptor arm is hence a key determinant for the interaction of AlbC with its second aa-tRNA substrate. The preference of AlbC for tRNA^LeuCAG^/tRNA^LeuCAG\*^ versus tRNA^LeuCAA^/ tRNA^LeuTAG^ may also be related to particular sequences in the acceptor arm. The best Leu-tRNA^Leu^ substrates (tRNA^LeuCAG^/tRNA^LeuCAG\*^) are the only substrates possessing the base pairs A^4^-U^69^ and A^5^•C^68^. The less efficient Leu-tRNA^Leu^ substrates (tRNA^LeuCAA^/ tRNA^LeuTAG^) share the sequences G^4^-C^69^ and A^6^-U^67^. Systematic mutational analysis will be required to clarify the involvement of these base pairs in the efficiency of substrate usage. The aminoacyl moiety of the second aa-tRNA also appears to be important for its interaction with the CDPS. Indeed, AlbC prefers Phe-tRNA^Phe^ to Leu-G^1^-C^72^ tRNA^LeuTAA^ as a second substrate, despite the fact that these two substrates have the same acceptor arm sequence. In addition, more cFF was synthesized than cFL for equivalent concentrations of Phe-tRNA^Phe^ and Leu-tRNA^Leu^. *In vivo*, AlbC produces more cFL than cFF ([@B2]). Dong and collaborators determined the abundances of tRNA in *E. coli* at different growth rates ([@B16]). Whatever the growth rate, there is about 9-fold more tRNA^Leu^ than tRNA^Phe^ in *E. coli* cells (about 7-fold more if we only consider tRNA^Leu^ isoacceptors that are efficiently used by AlbC). For a tRNA^Leu^/tRNA^Phe^ ratio representative of *in vivo* conditions, we indeed observed *in vitro* higher amounts of cFL than cFF.

In *E. coli*, all amino acids except Asn, Gln, Ile, Pro and Trp can be loaded onto tRNAs that contain a G^1^-C^72^ pair in the acceptor arm (<http://gtrnadb.ucsc.edu/Esch_coli_K12/Esch_coli_K12-align.html>). However, only a few of them can be incorporated into cyclodipeptides by AlbC as a second substrate, as shown by the cyclodipeptide production profile of recombinant *E. coli* producing AlbC ([@B2]). This clearly indicates that other determinants are important for the selection of the second substrate by AlbC. Phe, Leu, Tyr, Met and Ala amino acids are all incorporated into cyclodipeptides by AlbC. Closer examination of the sequences encoding tRNAs that are associated with these amino acids shows that these sequences all contain the G^1^-C^72^ pair as well as A^76^C^75^C^74^A^73^ in the single strand extremity. The rest of the sequence of these tRNAs, including the acceptor arm, is highly variable. Other *E. coli* tRNAs that possess the sequence A^76^C^75^C^74^A^73^C^72^-G^1^ can be charged with Arg, Lys or Val, but these amino acids are not incorporated by AlbC into cyclodipeptides. This definitely indicates that the selectivity of AlbC for its second substrate involves tRNA sequences but also the nature of the amino acid.

AlbC originates from *S. noursei*, therefore, we examined the tRNA sequences in this host. The sequences are not available for *S. noursei* but can be found for many other *Streptomyces* species. All the *Streptomyces* tRNA sequences contain A^76^C^75^C^74^A^73^C^72^-G^1^, suggesting that all tRNA^Phe^ and tRNA^Leu^ are substrates for AlbC. The acceptor arm of one *Streptomyces* tRNA^Leu^ isoacceptor, tRNA^LeuTAA^, is identical to that of *E. coli* tRNA^Phe^. The sequence of this tRNA^LeuTAA^ is highly conserved in *Streptomyces* species and this tRNA recognizes a rare codon. tRNA^LeuTAA^ has been thoroughly studied: it is not required for growth but is required for some aspects of secondary metabolism and morphological development ([@B17]). This tRNA would be particularly involved in regulatory pathways of biosynthesis of several antibiotics. Its potential relationship with AlbC remains to be determined.

In view of these results with AlbC, one may wonder if other CDPSs share the same key determinants for the first and the second aa-tRNA substrate. Like AlbC, most of the biochemically characterized CDPSs are promiscuous and synthesize several cyclodipeptides. One exception to this rule is the CDPS Amir_4627 from *Actinosynnema mirum*, which synthesizes exclusively cWW when this enzyme is expressed in *E. coli* ([@B18]). The sequence of the *E. coli* tRNA^Trp^ contains the combination of an A^1^-U*^72^* base pair and a G^73^ residue, which is a unique feature of tRNA^Trp^ in *E. coli*. This could contribute to the selectivity of Amir_4627 for its second amino acid substrate. The tRNA sequence of the second substrate may also be critical for the determination of the activity of eukaryotic CDPSs in *E. coli*. The CDPS *Nvec*-CDPS2 from the eukaryotic organism *Nematostella vectensis* mainly synthesizes cWX cyclodipeptides when it is expressed in *E. coli* ([@B7]). The base at position 73 of the tRNA^Trp^ acceptor arm is largely responsible for the very low cross reactivity between archeal or eukaryotic and bacterial TrpRS-tRNA^Trp^ pairs: this base is generally adenine in archeal or eukaryotic tRNA^Trp^ and guanine in bacterial tRNA^Trp^ ([@B19]). Expression of this CDPS in *E. coli* results in the synthesis of very small amounts of cWM, cWF and cWL. A search for tRNA^Trp^ sequences in the genome available for *N. vectensis* (<http://www.ncbi.nlm.nih.gov>) revealed five different sequences possessing characteristics of eukaryotic tRNA^Trp^. However, the acceptor arm sequences of these five candidates are more similar to *E. coli* tRNA^Phe^ or tRNA^Met^ than to *E. coli* tRNA^Trp^ (Supplementary Figure S6). Thus, an experimental system that uses eukaryotic tRNAs would probably give a more accurate view of *N. vectensis* CDPS activity. It follows that care must be taken when interpreting the results of activities of CDPSs expressed in *E. coli*: discrepancies between *E. coli* tRNA sequences and tRNA sequences in the species from which the CDPSs originates can give a misleading view of the activity of these enzymes in their natural environment.

The second important result of our work concerns the identification of two different regions of AlbC that interact with either the tRNA moiety of the first or that of the second substrate. We show that the basic patch of helix α4 is important for the binding of the first substrate. All the substitutions involving amino acids in this patch dramatically affected enzymatic activity *in vitro*, probably by perturbing the binding of the tRNA moiety. This indicates that all these residues, in particular R98 and R99, participate in the interaction. The basic patch does not belong to a clearly defined class of RNA-binding motif. It nevertheless shares features with some of them ([@B20]). In particular, the drastic decrease of enzymatic activity that is associated with substitutions of any residues of the motif has also been described for double-stranded RNA-binding motifs ([@B20],[@B21]). Arginines are essential residues for RNA binding. They are involved in non-specific interactions mediated by their positive charge. However, they also participate in specific hydrogen bonding networks with RNA bases, especially guanines ([@B20],[@B22],[@B23]). The occurrence of arginine•guanine pairs in specific RNA--protein interactions is very high in complex structures ([@B24]). The sequences of all the acceptor stems of aa-tRNAs used as substrates by AlbC have a high GC content, which is consistent with RNA--protein interactions involving arginines. Nonetheless, many new putative CDPSs that have been identified by Basic Local Alignment Search Tool searches ([@B3]) are devoid of the basic patch that is found in AlbC and other characterized CDPSs ([@B2],[@B5]). These putative CDPSs possess a large number of aspartic and glutamic acids, asparagine, glutamine, serine and threonine at a similar position to the basic patch of AlbC. These residues are known to interact specifically with nucleotide bases other than guanine. Thus, residues of helix α4 of these putative CDPSs may in part determine substrate specificity by interacting only with a limited number of tRNA sequences.

We found that the binding of the second substrate was affected when residues belonging to the loop α6--α7 or loop β6--α8 were substituted for alanine. In particular, binding was strongly affected in D163A (in loop α6--α7) and D205A (in loop β6--α8). In both TrpRSs and TyrRSs, the loop equivalent to this loop α6--α7 is involved in tRNA binding ([@B25]). Furthermore, during the binding of the second substrate, AlbC discriminates between G^1^-C^72^ and C^1^-G^72^, similar to TyrRSs and TrpRSs ([@B14],[@B15],[@B19]). This discrimination can be only achieved if the interaction of the enzyme with its substrate occurs from the major groove side of the acceptor stem ([@B22],[@B23]), which is also a distinctive feature of class-Ic aaRSs ([@B27],[@B28]), apparently shared by AlbC. This suggests that CDPSs may have retained some characteristics of class-Ic aaRSs regarding their interaction with their second substrate. In TyrRSs, a second cluster of amino acids belonging to the Rossmann-fold is involved in N^1^ recognition ([@B27]). In AlbC, this region corresponds to residues of helix α8 (P207-L212) and part of the following loop. Although AlbC has none of the consensus sequences that allow TyrRSs to specifically recognize G^1^-C^72^ or G^1^-C^72^ ([@B31]), mutational analysis of this region should be carried out to test its possible involvement in tRNA binding.

Both residues D205, which neighbours helix α8, and D163 from the loop α6--α7 appear to have a negative effect on catalytic activity, because substitution of these residues with alanine creates variants with higher catalytic activity. Such a phenomenon is not uncommon in enzymatic world ([@B32]). Both residues may be incorporated to improve enzyme specificity at the expense of efficiency, perhaps by preventing the binding of undesired tRNA sequences. Bedouelle *et al.* ([@B33]) identified such a residue in TyrRS from *Bacillus stearothermophilus*: the primary function of an acidic residue, E152, was to inhibit the use of non-cognate tRNAs by electrostatic and steric repulsions, and hence ensure enzyme specificity for tRNA^Tyr^. Another possibility is that D205 and D163 residues may reduce the affinity of cognate aa-tRNAs to AlbC so that the major fractions of Phe-tRNA^Phe^ and Leu-tRNA^Leu^ are used for ribosomal protein synthesis.

In conclusion, we demonstrate that AlbC handles differently its two substrates. The binding of its first substrate is highly dependent on the aminoacyl moiety of the tRNA, whereas both the aminoacyl moiety and the tRNA sequence itself are essential for the specific recognition of the second substrate. This first and second substrates bind to the enzyme at different sites: binding of the first substrate involves the basic patch centred on helix α4 whereas binding of the second substrate involves the loop α6--α7. These regions modulate the specificity of AlbC though specific interactions with appropriate tRNA sequences. Noted that the two binding sites could be simultaneously present on the enzyme or the second binding-site could result from a structural reorganisation induced by the formation of the aminoacyl-enzyme intermediate. The interaction of AlbC with its second aa-tRNA substrate shares features with the interaction of class-Ic aaRSs with their aa-tRNA substrates. Complementary biophysical analyses will be required to precisely define the outlines of these two binding sites and determine how many features CDPSs have retained from their aaRS ancestors.

SUPPLEMENTARY DATA {#SEC5}
==================

[Supplementary Data](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gku348/-/DC1) are available at NAR Online.

###### SUPPLEMENTARY DATA

We thank Cédric Masson for the purification of AlbC variants, Robert Thai for helpful advice about mass spectrometry, and Bertrand Czarny for use of the Beta-imager. We thank Fabrice Beau for useful discussions about enzymatic analyses. We are grateful to Emmanuelle Schmitt and Yves Mechulam for helpful discussions about aminoacyl-tRNA synthetases.

FUNDING {#SEC6}
=======

Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA); French National Research Agency (ANR). The Service d'Ingénierie Moléculaire des Protéines is a member of the Laboratory of Excellence LERMIT. Funding for open access charge: \[ANR 2010/BLAN 1501 01\].

*Conflict of interest statement*. None declared.
